Page last updated: 2024-12-09

3-Methoxycinnamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID637668
CHEMBL ID95769
CHEBI ID192607
SCHEMBL ID80786

Synonyms (59)

Synonym
CHEMBL95769 ,
LS-13767
3-(3-methoxyphenyl)prop-2-enoic acid
nsc5234
6099-04-3
nsc-5234
3-methoxycinnamic acid, 97%
m-methoxycinnamic acid
NCGC00174293-01
(2e)-3-(3-methoxyphenyl)prop-2-enoic acid
STK398162
(2e)-3-(3-methoxyphenyl)acrylic acid
17570-26-2
HMS1538H06
055FCE22-12AE-47AE-BB4F-BF75F6AECF94
cinnamic acid, 3-methoxy-
3-(3-methoxyphenyl)acrylic acid
o-methyl-m-coumaric acid
M0444
3-methoxycinnamic acid
o-methyl-m-cumaric acid
CHEBI:192607
(e)-3-(3-methoxyphenyl)prop-2-enoic acid
AKOS000120394
(e)-3-(3-methoxyphenyl)prop-2-enoate;3-methoxycinnamic acid
A832993
cinnamic acid, m-methoxy-, (e)-
trans-m-methoxycinnamic acid
2-propenoic acid,3-(3-methoxyphenyl)-, (2e)-
trans-3-(3-methoxyphenyl)acrylic acid
nsc 5234
einecs 228-049-5
trans-3-methoxycinnamic acid
AE-848/02128047
PS-5776
BBL019132
SCHEMBL80786
e-3-(3-methoxyphenyl)propenoic acid
trans-3-methoxy-cinnamic acid
(e)-3-methoxycinnamic acid
(e)-3-(3-methoxy-phenyl)-acrylic acid
(e)-3-(3-methoxyphenyl) acrylic acid
(e)-3-(3-methoxyphenyl)acrylic acid
2-propenoic acid, 3-(3-methoxyphenyl)-, (2e)-
propenoic acid, 3-(3-methoxyphenyl)-, trans-
(2e)-3-(3-methoxyphenyl)-2-propenoic acid #
cinnamic acid, m-methoxy-
W-105215
mfcd00004386
bdbm50486904
3-methoxycinnamic acid, predominantly trans
DTXSID70875904
Q63409580
(e)-3-(3-methoxyphenyl)acrylicacid ,
EN300-33979
CS-W017339
EN300-21248
2-propenoic acid,3-(3-methoxyphenyl)-,(2e)-
Z104494816
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxycinnamic acidAny member of the class of cinnamic acids carrying one or more hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1168274Inhibition of human recombinant PARP8 at 100 uM incubated for 1 hr using using NAD+, biotinylated NAD+ and activated DNA by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID1168275Inhibition of human recombinant PARP10 at 100 uM incubated for 1 hr using using NAD+, biotinylated NAD+ and activated DNA by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID1168276Inhibition of human recombinant PARP11 at 100 uM incubated for 1 hr using using NAD+, biotinylated NAD+ and activated DNA by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID1168272Inhibition of human recombinant PARP6 at 100 uM incubated for 1 hr using using NAD+, biotinylated NAD+ and activated DNA by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID1168251Inhibition of human recombinant PARP1 incubated for 1 hr using histone substrate at 20 nM by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID1168269Inhibition of human recombinant PARP1 incubated for 1 hr using histone substrate at 50 nM by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID1168271Inhibition of human recombinant PARP3 at 1 uM incubated for 1 hr using using NAD+, biotinylated NAD+ and activated DNA by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID1168277Inhibition of human recombinant PARP12 at 100 uM incubated for 1 hr using using NAD+, biotinylated NAD+ and activated DNA by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID1168273Inhibition of human recombinant PARP7 at 100 uM incubated for 1 hr using using NAD+, biotinylated NAD+ and activated DNA by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID1168270Inhibition of human recombinant PARP2 incubated for 1 hr using histone substrate at 50 nM by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID1631834Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms after 72 hrs by resazurin-based assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1168252Inhibition of human recombinant PARP2 incubated for 1 hr using histone substrate at 20 nM by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID37266Inhibition of alpha-glucosidase activity2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Structure-activity relationships of trans-cinnamic acid derivatives on alpha-glucosidase inhibition.
AID1168278Inhibition of human recombinant PARP14 at 100 uM incubated for 1 hr using using NAD+, biotinylated NAD+ and activated DNA by luminescence based assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Scaffold hopping approach on the route to selective tankyrase inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index33.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]